During the past decade, Retina Center Northwest conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 6 clinical trials were completed, i.e. on average, 35.3% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 6 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Center Northwest" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Kodiak Sciences Inc" with 3 trials sponsored, "Gyroscope Therapeutics Limited" with 2 trials sponsored, "Graybug Vision" with 1 trials sponsored and "IVERIC bio, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Center Northwest" #1 collaborator was "Novartis Pharmaceuticals" with 2 trials as a collaborator, "National Center for Complementary and Integrative Health (NCCIH)" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Office of Dietary Supplements (ODS)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Retina Center Northwest" are "Diabetic Macular Edema" (4 trials), "Geographic Atrophy" (4 trials), "Dry Age-related Macular Degeneration" (3 trials), "Neovascular Age-Related Macular Degeneration" (3 trials) and "Macular Degeneration" (2 trials). Many other conditions were trialed in "Retina Center Northwest" in a lesser frequency.

Most popular intervention types in "Retina Center Northwest" are "Drug" (16 trials), "Other" (5 trials), "Procedure" (2 trials), "Device" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept" (6 trials), "Sham Procedure" (6 trials), "Faricimab" (3 trials), "KSI-301" (3 trials) and "Intravitreal Ranibizumab 0.5 mg Injection" (2 trials). Other intervention names were less common.

The vast majority of trials in "Retina Center Northwest" are 18 trials for "All" genders.

Currently, there are NaN active trials in "Retina Center Northwest". undefined are not yet recruiting, 1 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Retina Center Northwest, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Center Northwest, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".